Skip to main content
. 2018 Jan 23;8:5. doi: 10.3389/fonc.2018.00005

Table 1.

Neoadjuvant chemotherapy phase II trials.

Reference Chemotherapy N N2 ORR (% total) Surgery (% total) R0 (% surgery) PCR (% total) Survival
Martini et al. (10) MVP 41 41 73 68 75 20 3 years 34%, 3 years 54% (R0),
Vokes et al. (11) EVP 27 NR 48 15 NR 0 Median 8 months
Pujol et al. (12) EPI 33 31 70 61 90 15 18 months 30%, median 10 months
Burkes et al. (13) MVP 39 39 64 56 82 8 3 years 26%, median 19 months
Martini et al. (14) MVP 136 136 77 84 78 14 3 years 28%, median 19 months; 3 years 41% (R0)
Darwish et al. (15) PE 46 46 80 72 85 9 2 years 53%, median 25 months
Sugarbaker et al. (16) VP 74 74 NR 85 37 0 3 years 23%, 3 years 46% (R0)
Elias et al. (17) P, 5-FU 34 34 65 82 75 18 Median 18 months
van Zandwijk et al.a (18) GP 47 47 70 NS NS NS Median 19 months
Betticher et al. (19) DP 90 90 66 83 48 16 EFS 15 months, median 33 months
O’Brien et al.a (20) CT 52 52 64 NS NS NS 1 year 68%, median 21 months
De Marinis et al. (21) GTP 49 49 74 59 93 16 1 year 85%, median 23 months
Cappuzzo et al. (22) GP 129 88 62 31 95 2 1 year 74%, median 19 months
Burkes et al. (23) MVP or VP 65 65 68 72 75 5 1 year 66%, median 19 months; 5 years 29%
Biesma et al.a (24) DP 46 46 39 NS NS NS 1 year 65%, median 16 months
Garrido et al. (25) GDP 136 69 53 66 69 6 3 years 37%, median 16 months; 5 years 41% (R0)
Chaft et al. (26) Bev, DP + Bev 50 NR 40 88 82 NR 3 years 64%
Ou et al. (27) C, Pem, Bev 42 36 42 74 71 NR 1 year 56%, median EFS 15.4 months

Bev, bevacizumab; C, carboplatin; D, docetaxel; EFS, event-free survival; E, etoposide; 5-FU, 5-fluorouracil; G, gemcitabine; I, ifosfamide; M, mitomycin-C; NR, not reported; NS, not significant; ORR, overall response rate P, cisplatin; V, PCR, pathologic complete response; Pem, pemetrexed; T, paclitaxel; vinblastine/vindesine.

aPatients in this trial were randomized to surgery or radiation after induction chemotherapy as part of the EORTC 08941.